Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home Public Health

Alzheimer’s panel at HJ23 will explore unanswered questions

admin by admin
February 25, 2023
in Public Health


Avatar photo

About Liz Seegert

Liz Seegert is an independent health journalist and AHCJ’s topic leader on aging. She covers older adults, baby boomers, health policy, and social determinants of health, as well as many other health issues. Her bylines include stories for PBS/NextAvenue.org. the American Journal of Nursing, TIME Health, Medscape, Consumer Reports, and Medical Economics, as well as dozens of other trade and mainstream media. Her articles have been syndicated in Forbes.com, the Los Angeles Times, the Hartford Courant, the Saturday Evening Post and other major outlets.

Photo courtesy of the National Institute on Aging

If any headline could sum up the state of research into Alzheimer’s disease it may be this: “Study reveals that much still not known about cognitive decline.”

Despite decades of research, there’s so much scientists have yet to learn about this degenerative disease. Risk factors, causes, amyloid plaque, tau tangles, Lecanemab, biomarkers and more are topics of dozens of research studies underway.

An expert panel will address these and other Alzheimer’s-related topics during the session Alzheimer’s update: What journalists can learn from latest research, at 4 p.m. CST on Friday, March 10, at Health Journalism ’23 in St. Louis. I’m moderating the discussion.

The panel comprises David Holtzman, M.D., scientific director of the Hope Center for Neurological Disorders, co-director of the Knight Alzheimer’s Disease Research Center, and former chair of neurology at Washington University, St. Louis; Suzanne Schindler, M.D., a Washington University clinical neurologist and dementia specialist whose recent research has been on developing and testing fluid (blood and CSF) biomarkers for Alzheimer’s disease; and Bryan James, Ph.D., an epidemiologist with the Rush Alzheimer’s Disease Center in Chicago. His research focuses on finding risk factors for the disease at the population level, and what social, lifestyle, and medical factors may protect against or increase vulnerability in the aging brain.

Targeted screenings and treatments for Alzheimer’s disease are highly complex and still not completely understood. We know some of the genetic and lifestyle risk factors, we know some of the associations between sleep, exercise, social isolation, medications and diet; but there’s so much yet to learn about Alzheimer’s. Known risk factors — including socioeconomic status, education and race — only explain about 38% of the variation in functioning among Americans at age 54, according to a study from Ohio State University.

One thing we do know: about 6 million people in the U.S. and 55 million people worldwide have the disease, according to estimates by the World Health Organization. By 2060, the CDC predicts Alzheimer’s will affect nearly 14 million people in the U.S., though some of what appears to be an increase is partly the result of the aging of the population.

Among the questions researchers are racing to answer:

  • Why does one person with plaques seem to be fine while others progress on a steep trajectory?
  • How do protective factors, like cognitive resilience, play a role in mitigating the disease?
  • Why has it taken so long to find a drug that only works for some people, some of the time?
  • What does clinical evidence reveal about brain degeneration in addition to amyloid beta and tau? Are there other forces at work?
  • Why do women seem to develop Alzheimer’s more frequently than men?
  • What do we know about the role of COVID in longer term memory impairment?

And can we please do something about those darn commercials that prey on hope and fear without any scientific basis? (OK, this one is a personal pet peeve.)

Here’s just a sampling of the interesting research that’s underway:

  • Last year, researchers identified a usable biomarker from blood samples to characterize early-stage Alzheimer’s disease (AD) patients, to facilitate rapid diagnosis, early therapeutic intervention, and monitoring of clinical trials.
  • The Alzheimer’s association is funding more than 950 active projects in 48 countries, where scientists are looking at everything from translational research and clinical interventions to molecular pathogenesis and physiology.
  • The NIH is funding hundreds of studies on, for example, new treatments, PET imaging, light and cognitive therapy and potential treatments for people with moderate-to-severe agitation due to the disease.
  • More institutions, including Rutgers University, are turning some of their focus to Alzheimer’s and dementia-related research and treatment.

We’ll touch on a lot of these developments during the March 10 session, so add it to your Whova agenda!

Liz Seegert is an independent health journalist and AHCJ’s topic leader on aging. She covers older adults, baby boomers, health policy, and social determinants of health, as well as many other health issues. Her bylines include stories for PBS/NextAvenue.org. the American Journal of Nursing, TIME Health, Medscape, Consumer Reports, and Medical Economics, as well as dozens of other trade and mainstream media. Her articles have been syndicated in Forbes.com, the Los Angeles Times, the Hartford Courant, the Saturday Evening Post and other major outlets.



Source link

Advertisement Banner
Previous Post

CleanTech® Automated Handwashing Stations vs. Industrial Trough Sinks

Next Post

Airway Management for Patients with Sleep Apnea

Related Posts

Public Health

Why environmental health is public health

March 25, 2023
Public Health

What are the Benefits of Using CleanTech® EVO for Hand Hygiene?

March 24, 2023
Public Health

HJ23 draws large crowd to the Gateway to the West

March 23, 2023
Public Health

Journalists need support and self-care when reporting on trauma 

March 18, 2023
Public Health

Top 2023 policy stories: end of public health emergency and telehealth

March 17, 2023
Public Health

What Markets are Ideal for CleanTech® EVO Automated Hand Hygiene?

March 17, 2023
Next Post

Airway Management for Patients with Sleep Apnea

Recommended

Saatva Mattress Review – The Sleep Doctor

5 months ago

As Balwani and Holmes Head To Jail…Will Others in Health Tech Follow? – The Health Care Blog

4 months ago

Applications open for Health Journalism 2023 fellowships

3 months ago

Mild to Moderate Cerebral Palsy in Young Children Treated with Vibration Therapy

2 months ago

Nursing Compassion Fatigue and Burnout vs. Moral Injury

2 months ago

© 2022 Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.